Come end of this month, representatives from a UK university will be in Singapore to discuss the possibilities of collaboration with PSS. The potential areas of collaboration will cover the specialties in the drug regulatory sciences and related industrial field.
In the last issue of eBulletin, we reported as a news brief about “The Never Ending IP Tussle with the Generics”. That tussles have indeed not settling; in fact, there is every sign to show that they escalate further!
Check out the following events and notice. Do take note and mark them on your calendar. Thanks very much.
? EMEA Recommends Suspension of marketing authorisation (MA) of efalizumab (RaptivaTM) due to potentials for severe side effects.
Here are a few brief news related to healthcare & pharmaceutical scenes for your quick update.
Calling all PSS members: Have you renewed your membership yet?
Click on Instructions for payment modes to renew
